This is a clinical study of patients with advanced malignancies who have failed previous standard clinical therapy or for whom no suitable and effective treatment is currently available. Soventinib is a selective anti-tumor agent with an anti-neoangiogenic target. More than 40 patients with advanced cancer have been enrolled in this study. You will receive free study medication and study-related tests during the study and a subsidy of 6,000 RMB. The use of soventinib may improve your disease status, improve your quality of life, and extend your life. Soventinib is an oral tablet that is easy to administer and reduces the amount of time patients need to spend in the hospital. Patient participation in this study means closer follow-up, so that patients can be monitored earlier for disease progression or progress, if it occurs. The patient’s participation may provide assistance to other patients who need this treatment.